8-K: Relmada Therapeutics Reports Q3 2026 Results, Advances Drug Development

Relmada Therapeutics announced third quarter 2026 financial results, highlighting progress in its NDV-01 and sepranolone programs, with IND submissions anticipated by year-end 2026 and substantial cash reserves funding operations through 2029.

Summary

• Relmada Therapeutics reported its third quarter 2026 financial results and provided a business update.
• The company is on track to submit Investigational New Drug (IND) applications for NDV-01 and sepranolone by the end of 2026.
• Phase 3 clinical trial program for NDV-01, named SPECTRUM, is set to commence upon IND clearance.
• Initial 18-month data from the NDV-01 Phase 2 study shows continued durability of response in patients with non-muscle invasive bladder cancer (NMIBC).
• The company reported cash, cash equivalents, and short-term investments of approximately $202.1 million as of September 30, 2026, which is expected to fund operations through 2029.
• Research and development expenses increased to $9.2 million for Q3 2026 from $4.0 million in Q3 2025, primarily due to study preparation and manufacturing costs.
• Net loss for Q3 2026 was $13.9 million, or $0.12 per share, compared to a net loss of $10.1 million, or $0.30 per share, in Q3 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, with significant progress on clinical trial timelines and strong cash reserves, balanced by the inherent risks of clinical-stage biotechnology development.

Positives

• NDV-01 CMC program on track for IND submission by year-end 2026, with Phase 3 SPECTRUM program initiation upon IND clearance.
• Long-term extension Phase 2 data for NDV-01 demonstrate continued durability of response: 86% of 12-month complete responders remained in complete response at 18 months.
• No Grade 3 treatment-related adverse events or discontinuations observed in the NDV-01 Phase 2 study through 18 months.
• Cash, cash equivalents, and short-term investments of approximately $202.1 million as of September 30, 2026, are expected to fund operations through 2029.
• Sepranolone IND submission is on track for year-end 2026, with Phase 2b trial in Prader-Willi Syndrome expected upon IND clearance.
• FDA has confirmed alignment on two registrational pathways for NDV-01 in NMIBC.

Negatives

• Research and development expenses increased significantly to $9.2 million in Q3 2026 from $4.0 million in Q3 2025.
• Net loss for Q3 2026 was $13.9 million, an increase from $10.1 million in Q3 2025.
• Two BCG-nave patients in the NDV-01 Phase 2 study progressed to muscle-invasive disease (T2a) at the Month 15 assessment.
• General and administrative expenses increased to $3.9 million in Q3 2026 from $3.1 million in Q3 2025 (corrected from filing, which states decrease, but numbers show increase).

Risks

• Potential for Relmada's product candidates to fail to progress in clinical trials.
• Clinical trials may fail to deliver statistically and/or clinically significant evidence of efficacy and/or safety.
• Failure of interim or top-line results to accurately reflect complete trial results.
• Potential failure to secure FDA agreement on the regulatory path for NDV-01 and/or sepranolone.
• Changes to the design, size, or timing of the Phase 3 SPECTRUM studies.
• Failure to successfully execute manufacturing and CMC activities for NDV-01 and/or sepranolone.
• Failure to secure adequate drug supply for NDV-01 and/or sepranolone.
• Patent applications may not result in issued patents or may be challenged and invalidated.

Future Outlook

The company anticipates submitting IND applications for both NDV-01 and sepranolone by the end of 2026. The Phase 3 SPECTRUM program for NDV-01 is expected to initiate upon IND clearance, and the Phase 2b trial for sepranolone in Prader-Willi Syndrome is also planned to commence post-IND clearance. The current cash position is projected to fund operations through 2029.

Management Comments

• "Relmada has made significant progress in advancing the NDV-01 CMC program and remains on track to submit the NDV-01 IND by year-end 2026. Furthermore, we have established a manufacturing plan to provide uninterrupted clinical supply through the completion of the Phase 3 SPECTRUM program."
• "Initial 18-month results from the ongoing NDV-01 Phase 2 study demonstrate extended durability of complete response and continued favorable tolerability."
• "Our Phase 3 program remains unchanged, with two independent registrational pathways in NMIBC, and we have renamed it SPECTRUM to reflect the potential breadth of NDV-01 across the NMIBC disease spectrum. We expect to begin the SPECTRUM program upon IND clearance."

Industry Context

StockSavvy.ai notes that Relmada Therapeutics operates in the competitive oncology and CNS therapeutic space. The company's focus on NMIBC addresses a significant unmet need, particularly in the high-risk BCG-unresponsive segment. The development of NDV-01 as a sustained-release intravesical therapy positions it against existing treatments, aiming for improved efficacy and patient convenience. The sepranolone program targets rare CNS disorders, leveraging GABA modulation, an area with growing research interest.

Comparison to Industry Standards

• The 86% durability of complete response at 18 months in the NDV-01 Phase 2 study for NMIBC is a strong indicator, though direct comparison to industry standards requires full Phase 3 data. Current treatments for BCG-unresponsive NMIBC have varying efficacy and durability profiles.
• The cash runway extending through 2029 for a clinical-stage biotech company is generally considered robust, providing ample time for clinical development milestones.
• The increase in R&D expenses is typical for companies advancing late-stage clinical assets, aligning with industry norms for companies in similar development phases.

Stakeholder Impact

• Shareholders: The update provides positive news regarding clinical development timelines and financial runway, potentially supporting investor confidence. However, the increased net loss and R&D spend reflect ongoing investment without immediate revenue.
• Patients: Continued progress in NDV-01 and sepranolone development offers potential future treatment options for NMIBC and CNS disorders.
• Employees: Increased R&D and G&A expenses may indicate continued investment in personnel and operations.

Next Steps

• Submit NDV-01 IND by year-end 2026.
• Initiate registrational Phase 3 SPECTRUM program for NDV-01 upon IND clearance.
• Submit sepranolone IND by year-end 2026.
• Initiate Phase 2b trial for sepranolone in Prader-Willi Syndrome upon IND clearance.
• Continue enrollment and long-term follow-up for the ongoing NDV-01 Phase 2 study (TRGC-011).

Key Dates

Recommendation

Relmada Therapeutics is a clinical-stage biotech company with promising drug candidates, particularly NDV-01 for NMIBC. The company has a strong cash position and clear development milestones. However, the inherent risks associated with clinical trials, regulatory approvals, and the competitive landscape warrant a cautious 'hold' recommendation until further de-risking events, such as successful Phase 3 data or regulatory approvals, occur.

Keywords

NMIBC, NDV-01, Relmada Therapeutics, bladder cancer, clinical trials, oncology, Sepranolone, Prader-Willi Syndrome